NASDAQ:GANX
Gain Therapeutics, Inc.
- Stock
Last Close
1.07
30/08 20:00
Market Cap
21.66M
Beta: 0.35
Volume Today
555.18K
Avg: 82.23K
PE Ratio
−2.52
PFCF: −5.26
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|
average inventory | |||||||
average payables | 557.98K - | 761.00K 36.38% | 1.09M 43.67% | 1.47M 34.69% | |||
average receivables | 55.74K - | 90.08K 61.60% | 108.73K 20.71% | 173.23K 59.32% | |||
book value per share | -0.08 - | 2.31 3,113.02% | 3.43 48.08% | 1.59 53.61% | 0.97 39.15% | ||
capex per share | -0.00 - | -0.00 71.82% | -0.01 231.67% | -0.01 19.33% | -0.01 8.01% | -0.00 88.21% | |
capex to depreciation | -10.78 - | -5.34 50.48% | -2.17 59.32% | -6.08 180.24% | -1.85 69.53% | -0.18 90.09% | |
capex to operating cash flow | 0.01 - | 0.01 31.54% | 0.01 12.49% | 0.01 18.54% | 0.01 6.27% | 0.00 89.95% | |
capex to revenue | -0.39 - | -0.33 14.26% | -0.72 117.02% | -0.57 20.81% | -0.85 48.69% | -0.28 67.22% | |
cash per share | 0.05 - | 2.79 5,298.77% | 3.63 29.83% | 1.69 53.29% | 1.29 23.83% | ||
days of inventory on hand | |||||||
days payables outstanding | |||||||
days sales outstanding | 396.94 - | 841.25 111.94% | 251.28 70.13% | 270.61 7.70% | 1.60K 492.94% | ||
debt to assets | 0.30 - | 0.13 56.85% | 0.04 68.58% | 0.05 28.15% | 0.04 18.95% | ||
debt to equity | -0.45 - | 0.20 145.53% | 0.05 77.29% | 0.07 46.10% | 0.06 6.06% | ||
dividend yield | |||||||
earnings yield | -0.02 - | -0.03 98.40% | -0.12 256.47% | -0.25 111.24% | -0.47 87.93% | -0.52 10.66% | |
enterprise value | 65.53M - | 23.80M 63.68% | 19.93M 16.28% | 31.16M 56.37% | 31.78M 2.00% | ||
enterprise value over ebitda | -32.25 - | -7.06 78.12% | -1.45 79.46% | -1.76 21.63% | -1.43 18.96% | ||
ev to operating cash flow | -35.07 - | -7.35 79.06% | -1.61 78.06% | -2.12 31.61% | -1.68 20.57% | ||
ev to sales | 1.59K - | 824.08 48.06% | 120.77 85.35% | 222.38 84.14% | 575.93 158.98% | ||
free cash flow per share | -0.13 - | -0.32 150.13% | -1.22 278.64% | -1.23 0.78% | -1.25 1.69% | -1.45 16.43% | |
free cash flow yield | -0.01 - | -0.03 150.13% | -0.11 278.64% | -0.23 107.88% | -0.40 76.41% | -0.44 11.44% | |
graham net net | -0.13 - | 1.54 1,270.41% | 3.23 108.95% | 1.26 60.89% | 0.84 33.34% | ||
graham number | 0.80 - | 8.33 936.36% | 10.26 23.15% | 7.27 29.11% | 6.10 16.13% | ||
income quality | 0.67 - | 0.85 26.49% | 0.91 6.32% | 0.89 1.71% | 0.84 6.18% | 0.85 1.44% | |
intangibles to total assets | 0 - | 0 | 0 | 0.01 Infinity% | 0.01 70.84% | 0 100% | |
interest coverage | 71.86 - | ||||||
interest debt per share | 0.03 - | 0.47 1,271.82% | 0.16 66.36% | 0.09 45.39% | 0.06 29.07% | ||
inventory turnover | |||||||
invested capital | -0.45 - | 0.20 145.53% | 0.05 77.29% | 0.07 46.10% | 0.06 6.06% | ||
market cap | 65.63M - | 65.63M 0% | 30.03M 54.24% | 55.20M 83.80% | 37.19M 32.62% | 42.55M 14.39% | |
net current asset value | -680.62K - | 5.59M 920.65% | 33.55M 500.75% | 15.87M 52.70% | 11.75M 25.98% | ||
net debt to ebitda | 0.05 - | 1.85 3,566.50% | 2.56 38.83% | 0.34 86.69% | 0.48 41.71% | ||
net income per share | -0.19 - | -0.37 98.40% | -1.33 256.47% | -1.37 2.41% | -1.48 8.33% | -1.71 15.61% | |
operating cash flow per share | -0.13 - | -0.32 150.97% | -1.21 278.99% | -1.22 0.67% | -1.24 1.64% | -1.45 17.28% | |
payables turnover | |||||||
receivables turnover | 0.92 - | 0.43 52.82% | 1.45 234.79% | 1.35 7.15% | 0.23 83.13% | ||
research and ddevelopement to revenue | 40.12 - | 38.41 4.28% | 78.22 103.67% | 43.42 44.49% | 59.79 37.70% | 208.78 249.18% | |
return on tangible assets | -3.32 - | -0.37 88.79% | -0.36 3.85% | -0.74 105.62% | -1.20 62.48% | ||
revenue per share | 0.00 - | 0.01 100.40% | 0.01 52.83% | 0.02 50.69% | 0.01 27.36% | 0.00 64.03% | |
roe | 4.88 - | -0.58 111.83% | -0.40 30.84% | -0.93 133.54% | -1.77 90.00% | ||
roic | 43.93 - | -0.44 100.99% | -0.37 15.11% | -0.86 131.70% | -1.63 89.90% | ||
sales general and administrative to revenue | 10.77 - | 13.44 24.76% | 43.25 221.76% | 41.38 4.33% | 68.09 64.56% | 195.50 187.12% | |
shareholders equity per share | -0.08 - | 2.31 3,113.02% | 3.43 48.08% | 1.59 53.61% | 0.97 39.15% | ||
stock based compensation to revenue | 2.83 - | 5.09 79.97% | 10.89 114.16% | 59.06 442.11% | |||
tangible asset value | -449.86K - | 6.20M 1,478.66% | 34.61M 458.13% | 18.67M 46.08% | 12.58M 32.61% | ||
tangible book value per share | -0.08 - | 2.31 3,113.02% | 3.41 47.22% | 1.57 53.87% | 0.97 38.45% | ||
working capital | -449.53K - | 6.87M 1,628.94% | 35.17M 411.71% | 16.97M 51.76% | 12.83M 24.38% |
All numbers in USD (except ratios and percentages)